Amylyx Pharmaceuticals, Inc.’s amyotrophic lateral sclerosis drug AMX0035 (sodium phenylbutyrate/taurursodiol) appears on track for US Food and Drug Administration approval following a strongly favorable vote at its second advisory committee review.
In voting 7-2 for approval, four members of the Peripheral and Central Nervous System Drugs Advisory Committee switched their votes...





